Celonis IPO before 2027?

As of September 1, 2026, Polymarket prices “Celonis IPO before 2027?” at 5% YES with $211K traded. No tracked wallet holds a position on this market, so there is no verdict.

Prediction markets put the probability at 6%: Celonis IPO before 2027. Currently, markets see this as unlikely (6% YES). Celonis IPO Celonis is a private company and has not had an IPO.

What’s Happening

Trading on the Nasdaq Private Market shows **Celonis** remains a privately held entity with no official IPO filing as of **August 17, 2026**, according to the platform's data intelligence database. The process-management software firm, valued at over **$13 billion** in its last primary funding round, has not set a price range or selected an exchange, leaving secondary-market participants to price the stock based on limited liquidity. This stands in contrast to peers like **Rippling** and **Anduril**, which have seen their pre-IPO share volumes climb to **$10.5 million** and **$10.5 million** respectively, indicating active institutional interest in those names ahead of potential listings [Nasdaq Private Market, Aug 17].

The market's **94% probability** that Celonis will not complete an IPO before **2027** reflects a broader slowdown in European tech listings, with only **7** venture-backed software companies going public on major U.S. exchanges in the first half of 2026, down from **23** in the same period last year. Historically, when the average time from Series E to IPO stretched beyond **42 months**—as it has for Celonis, now at **51 months** since its 2022 Series E—the likelihood of a near-term listing drops sharply. Macro conditions reinforce this: the **10-year Treasury yield** has hovered near **4.8%** since June, and the **CBOE IPO Index** has underperformed the S&P 500 by **11 percentage points** year-to-date, making new issuance less attractive for both underwriters and late-stage investors [Myriad, Aug 07].

Looking ahead, the key catalyst for a Celonis IPO would be a sustained drop in the **VIX** below **15** and a stabilization in the **2s10s yield curve**, which has been inverted for **14 consecutive weeks**—a signal that historically precedes weaker equity demand for unprofitable growth companies. Celonis reported **$450 million** in annual recurring revenue for 2025, but its **negative free cash flow margin** of **-18%** remains a hurdle for public market investors demanding profitability. If the Federal Reserve signals a rate cut at its **September 2026** meeting, the probability window could shift, but as of now, no S-1 filing has been submitted to the SEC, and the company has not hired a CFO with public-company experience—a prerequisite typically completed **6-9 months** before a filing [Nasdaq Private Market, Aug 17].

Traded on Polymarket — $211K Volume